Paper Details

  1. Home
  2. Paper Details

Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.

Author: De SantisGaetano, GuariniAttilio, IsidoriAlessandro, LoscoccoFederica, MazzaPatrizio, MustoPellegrino, PaolasiniSara, PastoreDomenico, PavoneVincenzo, PerroneTommasina, ScalzulliPotito, TarantiniGiuseppe, TonialiniLorenzo, VisaniGiuseppe

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Idelalisib is a PI3Kδ inhibitor approved for relapsed/refractory follicular lymphoma (FL). This study evaluated the efficacy and safety of idelalisib in a real-life setting, demonstrating a high response rate and manageable side effects, confirming its value in FL treatment.
Paper Details　
Original Abstract of the Article :
Idelalisib, a reversible inhibitor of PI3Kδ (phosphoinositide-3 kinase delta), showed remarkable activity in the phase II DELTA trial, leading to its approval by the European Medicines Agency (EMA) in patients with relapsed/refractory (R/R) follicular lymphoma (FL). However, real-life data on idelal...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/bjh.18426

データ提供：米国国立医学図書館（NLM）

Idelalisib: A Real-World Look at Its Effectiveness

Idelalisib, a targeted therapy for follicular lymphoma (FL), has shown promise in clinical trials. This study investigates the real-world efficacy and safety of idelalisib in patients with double-refractory FL, meaning their lymphoma has not responded to standard treatments. The researchers analyzed the outcomes of patients who received idelalisib in a real-world setting, providing insights into its effectiveness in routine clinical practice.

Idelalisib's Impact on Real-World Patients

The study found that idelalisib had a significant impact on patients with double-refractory FL. The drug achieved a high response rate, with a majority of patients experiencing a reduction in their lymphoma.

Hope for Patients with Double-Refractory FL

This study offers hope for patients with double-refractory FL, suggesting that idelalisib can be an effective treatment option even in challenging cases. The drug's effectiveness in a real-world setting underscores its potential for improving outcomes for patients with this aggressive form of lymphoma.

Dr.Camel's Conclusion

This study provides a real-world perspective on the effectiveness of idelalisib in treating double-refractory FL. The findings suggest that idelalisib can be a valuable treatment option for patients with this challenging condition. The drug's efficacy and safety in real-world settings provide hope for improving outcomes for patients with aggressive forms of lymphoma.

Date :
  1. Date Completed 2022-10-24
  2. Date Revised 2022-11-02
Further Info :

Pubmed ID

36002151

DOI: Digital Object Identifier

10.1111/bjh.18426

Related Literature

Article Analysis
・Effects of idelalisib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.